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AbsTrACT
background Several factors have been reported that 
influence the probability of a germline CDKN2A mutation 
in a melanoma family. Our goal was to create a scoring 
system to estimate this probability, based on a set of 
clinical features present in the patient and his or her 
family.
Methods Five clinical features and their association 
with CDKN2A mutations were investigated in a training 
cohort of 1227 Dutch melanoma families (13.7% with 
CDKN2A mutation) using multivariate logistic regression. 
Predefined features included number of family members 
with melanoma and with multiple primary melanomas, 
median age at diagnosis and presence of pancreatic 
cancer or upper airway cancer in a family member. 
Based on these five features, a scoring system (CDKN2A 
Mutation(CM)-Score) was developed and subsequently 
validated in a combined Swedish and Dutch familial 
melanoma cohort (n=421 families; 9.0% with CDKN2A 
mutation).
results all five features were significantly associated 
(p<0.05) with a CDKN2A mutation. at a cM-Score 
of 16 out of 49 possible points, the threshold of 10% 
mutation probability is approximated (9.9%; 95% ci 9.8 
to 10.1). this probability further increased to >90% for 
families with ≥36 points. a cM-Score under 16 points 
was associated with a low mutation probability (≤4%). 
cM-Score performed well in both the training cohort 
(area under the curve (aUc) 0.89; 95% ci 0.86 to 0.92) 
and the external validation cohort (aUc 0.94; 95% ci 
0.90 to 0.98).
Conclusion We developed a practical scoring system 
to predict CDKN2A mutation status among melanoma-
prone families. We suggest that CDKN2A analysis should 
be recommended to families with a cM-Score of ≥16 
points.
InTroduCTIon
Since its identification in 1994,1 the CDKN2A 
gene (MIM 600160) has remained the major high-
risk susceptibility gene for cutaneous melanoma. 
Germline mutations are present in approximately 
10%–40% of familial cases.2 Carriers of a germline 
mutation in the CDKN2A gene have an increased 
risk for developing melanoma, with a penetrance of 
up to 70% at 80 years of age, and 40% of carriers 
develop multiple primary cutaneous melanomas.3 
Furthermore, mutation carriers have an increased 
risk for other types of malignancies, the most 
important of which is pancreatic cancer (PC).4 Due 
to the high risk of melanomas and other types of 
cancer and the advantages of regular surveillance in 
improving prognosis and survival,5 6 it is important 
to identify families that carry a CDKN2A germline 
mutation. However, the probability of a CDKN2A 
mutation strongly depends both on the clinical 
characteristics of a family and personal (dermato-
logical) and environmental factors such as skin type 
and the amount of sun exposure. Thus, CDKN2A 
mutation analysis might not be indicated in some 
lower-risk melanoma families.
The Netherlands and Sweden both have a high 
incidence of melanoma (age-standardised rate 19.4 
and 18.0 per 100 000, respectively)7 and specific 
founder mutations in the CDKN2A gene are the 
predominant cause of familial melanoma in these 
countries. In the Netherlands, the 19-base pair 
deletion termed p16-Leiden (c.225_243del, p.Ala-
76Cysfs*64; RefSeq NM_000077.4) confers an 
increased risk for melanoma and for tumours of the 
pancreas and upper airway tract (larynx, pharynx, 
oral cavity) and to a lesser extent tumours of the 
lungs and digestive tract.8–10 Carriers of the Swedish 
founder mutation (c.335_337dup, p.Arg112dup; 
RefSeq NM_000077.4) also show an increased risk 
for these tumours.11 12 Although it is recognised 
that the risk-spectrum for non-melanoma cancers 
differs among carriers of different mutations in the 
CDKN2A gene, pancreatic and upper airway tract 
cancers have repeatedly been reported in a variety 
of carrier populations.4 13–17
Over the past decade, research groups from 
Europe, USA and Australia have attempted to iden-
tify clinical features that are associated with germ-
line CDKN2A mutations in melanoma families.18–24 
Studied features included (1) number of patients 
with melanoma in a family, (2) number of patients 
with multiple primary melanomas (MPMs) in a 
family, (3) median age at diagnosis of melanoma 
and (4) presence of PC in a family. The most signif-
icant associations reported in these studies were 
the presence of more than two melanoma cases in 






 on 9 A












enet: first published as 10.1136/jm





662 Potjer TP, et al. J Med Genet 2018;55:661–668. doi:10.1136/jmedgenet-2017-105205
Cancer genetics
one family member with MPMs and/or PC. Based on a literature 
review from 2009, it was suggested that patients with melanoma 
from areas with a moderate to high incidence of melanoma are 
candidates for genetic testing of CDKN2A if they have at least 
three primary melanomas or when there are at least two addi-
tional diagnoses of melanoma and/or PC among close (first-de-
gree or second-degree) family members (‘rule of threes’).25 The 
authors argued that these families have an estimated 10% or 
greater probability of carrying a germline CDKN2A mutation, 
which is a commonly used threshold in clinical practice for gene 
sequencing in hereditary cancer.26–28
The goal of this study was to create a scoring system for clini-
cians to estimate the probability of a germline CDKN2A muta-
tion based on a set of clinical features present in the patient and 
his or her family. Using a training cohort of Dutch melanoma 
families, we therefore analysed the association of four previously 
reported clinical features that are associated with a CDKN2A 
mutation and investigated the association with upper airway 
cancer (UAC) as an additional feature. A combined cohort of 
Swedish and Dutch melanoma families was used for external 
validation of the scoring system.
PATIenTs And MeThods
Training cohort
The training cohort included all index patients with cutaneous 
melanoma and their families in the Netherlands referred for 
CDKN2A mutation analysis between 1998 and 2015. According 
to current Dutch referral guidelines, CDKN2A mutation analysis 
is indicated if one of the following criteria is met: a family with 
(1) two first-degree relatives with melanoma, (2) two first-degree 
or second-degree relatives with melanoma and one first-degree 
or second-degree relative with PC, (3) three or more primary 
melanomas in one individual, (4) an individual with juvenile 
melanoma (<18 years) or (5) an individual with a history of both 
melanoma and PC. At the Department of Clinical Genetics at 
Leiden University Medical Centre, the Laboratory for Diagnostic 
Genome Analysis (LDGA) has been the primary sequencing 
facility for CDKN2A in the Netherlands since 1998 and receives 
diagnostic requests from across the Netherlands. Essential pedi-
gree information was gathered for the families and added to 
the Leiden Familial Melanoma Database. These data included 
the number of first-degree and second-degree family members 
(of each other) with cutaneous melanoma (invasive or in situ), 
whether these patients had a single melanoma or MPMs, the age 
of each patient with melanoma at first diagnosis and the number 
of family members with PC and UAC, that is, cancer of larynx, 
pharynx or oral cavity. We restricted our analysis of these latter 
tumours to the first-degree and second-degree relatives of the 
index patient and the first-degree relatives of patients with mela-
noma. We relied on the referring clinical geneticists for complete 
pedigree information and, if necessary, histological confirmation 
of cancer diagnoses (melanoma and others). We included all 
information on cancer diagnoses and also those unconfirmed by 
the clinical geneticist, since index patient reports of melanomas 
in family members have a high known level of accuracy (true 
positive predictive value 77%–87%).29 We imputed the age of 
melanoma diagnosis for family members where the age at diag-
nosis was not reported in the pedigree (n=320 individuals from 
212 families (61 with CDKN2A mutation)). Imputation was 
based on median age at diagnosis in CDKN2A mutation families 
(40 years) and in sporadic (non-CDKN2A) patients (55 years), as 
reported by van der Rhee et al.30 When the patient was younger 
than this age or was deceased prior to this age at time of CDKN2A 
analysis in the family, that specific age was used for imputation. 
Families without a CDKN2A mutation were excluded from the 
study if CDKN2A analysis was only performed in a non-affected 
family member (n=84). Families in which CDKN2A sequencing 
was unsuccessful were also excluded (n=4). The Leiden Univer-
sity Medical Centre Ethics Committee issued a declaration of 
no objection (#C14.064) regarding the creation of the Leiden 
Familial Melanoma Database.
Validation cohort
The greater portion of the validation cohort in this study 
consisted of members of melanoma-prone families from 
Sweden.31 Families were identified by questioning patients with 
newly diagnosed melanoma about their familial melanoma 
history. Melanoma families were defined as kindreds with at 
least two relatives (first-degree, second-degree or third-degree) 
with histologically or clinically verified melanoma. Since 1995, 
germline CDKN2A mutation analysis is offered to members of 
these families after informed consent is obtained. The study was 
approved by Research Ethical Review Boards at Lund Univer-
sity and Karolinska Institute in Stockholm, the sites where the 
genetic tests were performed. In Stockholm, patients with MPMs 
(regardless of family history) are also invited to undergo germ-
line CDKN2A mutation analysis. In 2012, a study was performed 
to broaden understanding of the identified familial melanoma 
kindreds and of patients with MPMs through linkage to Swedish 
national registries.11 12 32 33 Further linkage to the Swedish 
Cancer Registry (established in 1958 with register completeness 
estimated to be 96%34) provided data on all registered cancers 
in the CDKN2A genotyped individuals and their first-degree and 
second-degree relatives.
Additional Dutch melanoma families were recruited at the 
Department of Dermatology, Leiden University Medical Centre, 
according to the inclusion criteria of the GenoMEL study (http://
www. genomel. org/). After providing written informed consent, 
patients with melanoma were asked about their familial mela-
noma history. A melanoma family was defined by the presence 
of three or more cases with histologically confirmed melanoma 
or two cases with histologically confirmed melanoma in first-de-
gree relatives.
dnA analysis
In the Dutch cohorts (both training and validation), DNA was 
extracted from whole blood samples of index patients and was 
used for sequencing of all coding exons of CDKN2A (1α, 1β, 
2 and 3), including exon/intron boundaries. To detect larger 
deletions or duplications, multiplex ligation-dependent probe 
amplification was performed. In the early years of CDKN2A 
diagnostics, analysis was limited to a mutation-specific PCR for 
the detection of the p16-Leiden mutation. However, only a very 
small subset of CDKN2A wild type families in the training cohort 
was analysed in this manner (n=32). In an additional 89 families 
from the training cohort, exon 1β was not sequenced. For the 
Swedish cohort, procedures used for PCR of all CDKN2A exons 
and direct sequencing of PCR products have been described 
previously.11 Presence of a CDKN2A mutation was defined 
as having either a pathogenic or likely pathogenic variant in 
the CDKN2A gene (class 4 or 5 variant)35 or an unclassified 
variant (class 3) shown to be located on a pathogenic CDKN2A 
haplotype. Classification of these variants was based on (previ-
ously reported) cosegregation with disease, strong evidence of 
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statistical analysis
Five clinical features were predefined and used for analysis: 
(1) the total number of first-degree and second-degree family 
members (including the index patient) with a diagnosis of mela-
noma, (2) the number of these family members with MPMs, (3) 
the median age at diagnosis of (first) melanoma in the family and 
the presence of (4) PC and (5) UAC in a family. Median age at 
diagnosis was divided into three age groups (<30 years, 30–50 
years and ≥50 years). A univariate analysis was performed to 
independently evaluate these features and a multivariate logistic 
regression model was used to assess the association between all 
five features and the presence of a germline CDKN2A muta-
tion. The formula of the logistic regression model is P(robabil-
ity)=eL/(1+eL) where L=constant + β1*C1 (number of family 
members with melanoma [1=0, 2=1, 3=2, ≥4=3]) + β2*C2 
(number of family members with MPMs [0=0, 1=1,≥2=2]) + 
β3*C3 (median age at primary diagnosis [≥50=0,<50=1]) + 
β4*C4 (presence of PC [No=0, Yes=1]) + β5*C5 (presence of 
UAC [No=0, Yes=1]) and where β is the feature-specific β-coef-
ficient. All statistical analyses were carried out in SPSS V.23.0.
development of a scoring system: CM-score
The β-coefficients derived from the multivariate analysis 
were converted to points for each feature using the formula 
Points=(Cx*βC)/B (as described by Sullivan et al,
36 where Cx is 
the feature-specific numeral from the logistic regression formula, 
βC is the β-coefficient and B is the fixed multiplier or constant 
(defined 0.22). The total number of points was calculated for 
each family in the training cohort. Since there were often consid-
erable differences in the number of families with successive 
point totals (for instance, there were 6 families with 21 points 
(33% mutation) and 37 families with 22 points (16% muta-
tion)), the cohort was subsequently split into eight point-groups. 
This grouping would ensure a more accurate calculation of the 
observed mutation frequencies per group with narrower CIs. 
For each of these groups, the observed mutation frequencies, 
the mean of the predicted probabilities and their 95% CIs were 
calculated. The scoring system, CM-(CDKN2A Mutation) Score, 
was subsequently applied to the validation cohort, with the fami-
lies split into the same point-groups as in the training cohort. 
The observed mutation frequencies and their 95% CIs were again 
calculated for each group. The performance of the scoring system 
was assessed for both the training cohort and the validation cohort 
with the Hosmer-Lemeshow goodness of fit test (calibration) 
and receiver operator characteristic (ROC) curve analysis with 
calculation of the area under the curve (AUC) (discrimination). 
The slope of the calibration line was estimated with linear regres-
sion. The proposed cut-off value in CM-Score for performing 
CDKN2A analysis was determined as the score that corresponds 
to a predicted mutation probability of ~10%.26–28
resulTs
Training cohort
A total of 1227 families were included in the study, 168 of which 
had a (likely) pathogenic variant in the CDKN2A gene (13.7%). 
The p16-Leiden founder mutation was present in 77% of these 
families (n=130) (online supplementary table S1). Most of the 
families had two or more members with melanoma (853 fami-
lies; 70%) and included 503 two-case families, 233 three-case 
families and 117 families with four or more melanoma cases. In 
654 (77%) of these multiple-case families, at least one additional 
clinical feature was present (ie, median age <50 years or pres-
ence of MPMs, PC or UAC in the family, see online supplemen-
tary table S2). In the 374 single-case families, 207 families (55%) 
had at least two other clinical features and 150 families (40%) 
had one other clinical feature. The majority of melanomas in the 
training cohort were confirmed by histology reports (76%). PC 
and UAC diagnoses were less frequently confirmed by the refer-
ring clinical geneticist (both 43%).
Table 1 Univariate analysis showing the independent association between each clinical feature and a germline CDKN2A mutation
Features Total (n=1227)
CDKN2A wild type 
(n=1059)
CDKN2A mutation 
(n=168) or* 95% CI P values
No of family members with melanoma†
  1 374 346 28 (7.5%) 1.0 – – 
  2 503 461 42 (8.3%) 1.1 0.7 to 1.9 0.641
  3 233 194 39 (16.7%) 2.5 1.5 to 4.2 <0.001
  ≥4 117 58 59 (50.4%) 12.6 7.4 to 21.3 <0.001
No of family members with MPMs†
  0 749 697 52 (6.9%) 1.0 – – 
  1 406 329 77 (19.0%) 3.1 2.2 to 4.6 <0.001
  ≥2 72 33 39 (54.2%) 15.8 9.2 to 27.3 <0.001
Median age at primary diagnosis
  ≥50 years 437 422 15 (3.4%) 1.0 – – 
  30–50 years 666 532 134 (20.1%) 7.1 4.1 to 12.3 <0.001
  <30 years 124 105 19 (15.3%) 5.1 2.5 to 10.4 <0.001
Presence of pancreatic cancer‡
  No 956 877 79 (8.3%) 1.0 – – 
  Yes 271 182 89 (32.8%) 5.4 3.9 to 7.6 <0.001
Presence of upper airway cancer‡ 
  No 1117 999 118 (10.6%) 1.0 – – 
  Yes 110 60 50 (45.5%) 7.1 4.6 to 10.7 <0.001
*The variable with the smallest risk was defined as baseline with an OR of 1.0, and ORs for the other variables were calculated against this baseline value.
†First-degree and second-degree relatives of each other, including the index patient.
‡First-degree and second-degree relatives of the index patient and first-degree relatives of patients with melanoma.
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univariate and multivariate analysis
Having at least three family members with melanoma was 
significantly associated with the presence of a CDKN2A muta-
tion in the univariate analysis (table 1). A median age of under 
50 years and one or more cases with MPMs in a family were also 
significantly associated with a CDKN2A mutation. Age under 30 
years at time of diagnosis did not result in a higher OR than age 
30–50 years (OR 5.1 (95% CI 2.5 to 10.4) versus OR 7.1 (95% 
CI 4.1 to 12.3), respectively). A significantly increased risk for 
a CDKN2A mutation was seen in families in which PC and UAC 
co-occurred with melanoma; a mutation was present in 33% of 
the families with one or more patients with PC and 46% of the 
families with one or more patients with UAC.
In a multivariate logistic regression model, the five features 
investigated in the univariate model remained significantly asso-
ciated with a mutation (table 2). Since in the univariate analysis, 
age under 30 years was not a stronger predictor than age 30–50 
years, these age groups were combined into one group (age <50 
years) for the multivariate analysis. The highest ORs were found 
for median age under 50 years (OR 8.5 (95% CI 4.5 to 16.0)) 
and for presence of PC or UAC in a family (OR 7.5 (95% CI 
4.8 to 11.7) and OR 6.0 (95% CI 3.4 to 10.5), respectively), 
but these features had only two possible outcomes (<50 or ≥50 
years, Yes or No), whereas the other melanoma-specific features 
had three or four possible outcomes and increasing ORs for each 
step.
CM-score
The points assigned to each clinical feature are shown in table 3. 
The predicted mutation probabilities and observed mutation 
frequencies per point-group are shown in table 4. Below a 
total of 16 of 49 possible points, the predicted mutation proba-
bility is low (≤4.0%). Between 16 and 19 points, the predicted 
mutation probability is 9.9% and substantially increases in 
subsequent point-groups (20–23 points: 20.9%, 24–27 points: 
34.7%, 28–31 points: 52.1%, 32–35 points: 71.4%,≥36 points: 
90.7%).
The concordance between observed and predicted mutation 
probabilities (calibration) is graphically displayed in figure 1A. 
The slope of the calibration line (1.03) indicates a good cali-
bration, and the Hosmer-Lemeshow test (p=0.925) provided no 
evidence of a poor fit. Figure 2A shows the ROC curve analysis. 
The AUC is 0.89 (95% CI 0.86 to 0.92, p<0.001), which indi-
cates that the model has a good ability to discriminate between 
families with and without a CDKN2A mutation. The threshold 
of 10% predicted probability is approximated at the cut-off value 
of 16 points in CM-Score, with a sensitivity of 90.5% (95% CI 
84.7 to 94.2) and a specificity of 68.0% (95% CI 65.1 to 70.8). 
The majority of families (n=736; 60%) had a CM-Score of less 
than 16 points.
external validation of the scoring system
The validation cohort consisted of a total of 421 families (403 
from Sweden; 18 from the Netherlands), of which 38 had a 
(likely) pathogenic variant in the CDKN2A gene (9.0%). Most of 
these families (n=30; 79%) carried the Swedish founder muta-
tion p.Arg112dup and two Dutch families carried the p16-Leiden 
founder mutation (online supplementary table S3). The majority 
were multiple-case families (294 families; 70%) and included 
232 two-case families, 37 three-case families and 25 families 
with four or more melanoma cases. All melanomas in the vali-
dation cohort were histologically confirmed. PC was present in 
29 families (28 histologically confirmed; 72% CDKN2A muta-
tion) and UAC in 24 families (23 histologically confirmed; 63% 
CDKN2A mutation).
The observed mutation frequencies per point-group in the 
validation cohort are shown in table 4. The performance of 
CM-Score in the validation cohort is displayed in figures 1B and 
2B. The slope of the calibration line is 1.14 with a non-signifi-
cant Hosmer-Lemeshow test (p=0.615). The AUC is 0.94 (95% 
CI 0.90 to 0.98, p<0.001), indicating good performance of 
CM-Score in the validation cohort. The sensitivity and speci-
ficity at the cut-off value of 16 points is 89.5% (95% CI 74.3 
to 96.6) and 83.8% (95% CI 79.6 to 87.3), respectively. Similar 
to the training cohort, the majority of families in the validation 
cohort (n=325; 77%) had a CM-Score of less than 16 points.
Table 2 Multivariate logistic regression model showing the 
association between all five clinical features combined and a germline 
CDKN2A mutation
Clinical feature β-coefficient or 95% CI P values
No of family members with 
melanoma (1, 2, 3, ≥4)
0.871 2.4 1.9 to 3.0 <0.001
No of family members with 
MPMs (0, 1, ≥2)
1.096 3.0 2.2 to 4.1 <0.001
Median age at primary 
diagnosis (≥50, <50)
2.142 8.5 4.5 to 16.0 <0.001
Presence of pancreatic cancer 
(No, Yes)
2.013 7.5 4.8 to 11.7 <0.001
Presence of upper airway cancer 
(No, Yes)
1.790 6.0 3.4 to 10.5 <0.001
The formula of the logistic regression model:
P=eL/(1+eL) where L= −6.220 + 0.871 × C1 (no. of family members with 
melanoma [1=0, 2=1, 3=2, ≥4=3]) + 1.096 × C2 (no. of family members with 
MPMs [0=0, 1=1, ≥2=2]) + 2.142 × C3 (median age at primary diagnosis 
[≥50=0,<50=1]) + 2.013 × C4 (presence of pancreatic cancer [No=0, 
Yes=1]) + 1.790 × C5 (presence of upper airway cancer [No=0, Yes=1]).
MPMs, multiple primary melanomas.
Table 3 Scoring system (CM-Score) based on the multivariate logistic 
regression model
Features Points
No of family members with melanoma*
  1 0
  2 4
  3 8
  ≥4 12
No of family members with MPMs*
  0 0
  1 5
  ≥2 10
Median age at primary diagnosis
  ≥50 years 0
  <50 years 10
Presence of pancreatic cancer†
  No 0
  Yes 9
Presence of upper airway cancer†
  No 0
  Yes 8
*First-degree and second-degree relatives of each other, including the index patient.
†First-degree and second-degree relatives of the index patient and first-degree 
relatives of patients with melanoma.
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dIsCussIon
This study in a large Dutch training cohort of 1227 melanoma 
families confirmed the importance of four previously established 
clinical features that are associated with the presence of a germ-
line CDKN2A mutation in a patient with melanoma. Further-
more, a fifth feature, the presence of UAC in the family, could 
be validated. Based on these clinical features and their ORs in 
our multivariate logistic regression model, we developed the 
CM-Score system to predict CDKN2A mutation probability, 
which performed very well in a combined Swedish and Dutch 
external validation cohort (AUC 0.94). At a cut-off value of 16 
out of 49 points, the predicted probability approximates the 
commonly used 10% predicted probability threshold for germ-
line gene sequencing in hereditary cancer, with a sensitivity of 
89% and a specificity of 84% in the validation cohort. This 
cut-off value is also clinically relevant, since the majority of fami-
lies in the training and validation cohorts scored less than 16 
points (60% and 77%, respectively), a threshold below which 
the probability of a mutation decreases substantially (≤4%). Use 
of CM-Score could potentially spare many families (extensive) 
genetic testing, which may be particularly relevant in countries 
where resources for genetic testing are limited. Conversely, in 
families with a high CM-Score and therefore high mutation 
probability, genetic testing is even more urgent. A scoring system 
should, however, always only complement the clinical judge-
ment of the clinical geneticist requesting DNA diagnostics (for 
instance, taking into account family size, age of family members, 
whether a patient has a certain combination of different malig-
nancies and the availability of reliable medical information).
Risk models involving melanoma37 and CDKN2A mutation 
probability23 24 have been described previously. Niendorf et al 
incorporated the features (1) number of primary proband mela-
nomas, (2) number of primary melanomas in the family and (3) 
age in a logistic regression model they named MELPREDICT.23 
Table 4 Point totals from CM-Score with the corresponding mean predicted mutation probabilities and the observed mutation frequencies in the 
training and validation cohorts
CM-score Predicted mutation probability observed mutation frequency
Points Prob. (%)  95%  CI 
Training cohort (n=1227) Validation cohort (n=421) 
Freq. % 95%  CI Freq. % 95%  CI 
≤11 1.0 0.9 to 1.0 4/383 1.0 0.4 to 2.7 0/159 0 0.0 to 2.4
12–15 4.0 3.9 to 4.1 12/353 3.4 2.0 to 5.9 4/166 2.4 0.9 to 6.0
16–19 9.9 9.8 to 10.1 26/203 12.8 8.9 to 18.1 4/38 10.5 4.2 to 24.1
20–23 20.9 20.4 to 21.4 18/99 18.2 11.8 to 26.9 1/17 5.9 1.1 to 27.0
24–27 34.7 33.1 to 36.3 23/75 30.7 21.4 to 41.8 4/12 33.3 13.8 to 60.9
28–31 52.1 49.4 to  54.7 16/32 50.0 33.6 to 66.4 4/6 66.7 30.0 to 90.3
32–35 71.4 69.6 to  73.1 30/40 75.0 59.8 to 85.8 5/7 71.4 35.9 to 91.8
≥36 90.7 89.0 to  92.4 39/42 92.9 81.0 to 97.5 16/16 100 80.6 to 100.0
The predicted mutation probability for each point-group is the mean of the predicted probabilities of the point totals in that group in the training cohort. The corresponding 95% 
CI is estimated using the SE of the mean.
Freq, frequency; Prob, probability.
Figure 1 calibration of cM-Score. (a) training cohort. (B) Validation cohort. the calibration line (red) is a linear regression line that shows the relation 
between observed mutation frequency and predicted mutation probability in the training cohort (a) and the validation cohort (B). the dashed line is the 
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The AUC was 0.881 in the training set (n=116 families) and 
0.803 in the external validation set (n=143 families). A comput-
erised optimisation of this model, renamed MelaPRO, was 
published in 2010 and outperformed the former model with 
an AUC of 0.86 in a validation set of 167 families.24 MelaPRO 
includes the same clinical (familial) features as MELPREDICT, 
but also takes into account regional melanoma incidence rates 
and the geographical penetrance of CDKN2A. In contrast, 
while our CM-Score was trained and validated using families 
of Northern European descent, its strength lies in its simple, 
non-computerised scoring system that incorporates five features 
(including the presence of PC and UAC in a family) and despite 
this simplicity shows a superior performance in very large sets of 
melanoma-prone families.
The guidelines for CDKN2A mutation testing proposed by 
Leachman et al in 200925 were recently updated.38 In view of the 
recent reports of non-CDKN2A melanoma syndromes, such as 
those related to germline mutations in BAP139 (MIM 603089), 
POT140 (MIM 606478) and MITF41 (MIM 156845), the authors 
propose tailored multigene panel testing in melanoma families 
instead of CDKN2A mutation testing alone. The 2009 criteria for 
genetic testing were converted into a points system, with points 
awarded for cancers that occur in so-called melanoma-dominant 
syndromes and melanoma-subordinate syndromes (where mela-
noma is not the predominant cancer type, such as in hereditary 
breast and ovarian cancer). Based on these points, the clinical 
geneticist can subsequently select the appropriate gene panel(s) 
to be tested in a family. In the selection and genetic assessment 
of melanoma families, this is a rather different approach to the 
one we propose in the current study. First, CM-Score is designed 
for families where melanoma is the predominant cancer type. 
Second, since CDKN2A is still by far the major susceptibility 
gene in familial melanoma, we based the selection of families 
for genetic assessment on the probability of specifically detecting 
a CDKN2A mutation in these families. Because other melano-
ma-dominant syndromes (such as those related to BAP1, POT1, 
CDK4 and MITF) are very rare compared to CDKN2A-related 
familial melanoma (each gene contributing <1%),42 we hypoth-
esise that the calculated mutation probability from CM-Score 
largely reflects the joint probability of detecting a germline 
CDKN2A mutation or any other melanoma-dominant mutation. 
However, it should be noted that some tumours that are not 
part of CM-Score are highly specific to non-CDKN2A melanoma 
syndromes, especially BAP1-related tumours such as uveal mela-
noma and mesothelioma.43 44 BAP1 germline analysis should 
therefore be specifically offered when these tumours co-occur 
with cutaneous melanoma in a family, either together with 
CDKN2A or as part of a multigene panel test. It is not within the 
scope of this study to elaborate on the choice between multigene 
panel testing and CDKN2A mutation testing alone in melano-
ma-prone families. Although multigene panel testing increases 
the detection rate of cancer-predisposing germline mutations, 
there is also an elevated risk of identifying a variant of unknown 
significance in one of the genes and therefore increasing the 
uncertainty for a family regarding their genetic risk. The chance 
of this happening increases as more genes are included in a panel 
or when multiple panels are considered. Pros and cons of multi-
gene panel testing should therefore always be carefully discussed 
with the patient.
Strengths of our study include relatively large and homoge-
neous cohorts and the broad analysis of five clinical features, 
including one more recently described feature (ie, UAC). 
However, because the scoring system is based on populations 
with a high melanoma incidence, it is possible that it will under-
estimate the probability of finding a CDKN2A mutation in lower 
melanoma incidence areas such as Southern (Mediterranean) 
Europe or overestimate the probability in extreme incidence 
areas such as Australia. Additional validation in other geograph-
ical areas would therefore be valuable. Another limitation of 
our study is information bias. In the training cohort, we had to 
rely on information supplied by the referring clinical geneticists 
and not all melanoma diagnoses were therefore histologically 
Figure 2 Discriminative ability of cM-Score. (a) training cohort. (B) Validation cohort. rOc curve analysis of the training cohort (a) and the validation 
cohort (B). Point total was used as the test variable and mutation status was used as the state variable. comparable results were obtained when the 
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confirmed (76%). However, since the reporting of additional 
melanomas in family members by the index patient is known to 
be highly accurate, this factor is unlikely to have influenced the 
results.29 Unfortunately, only 43% of all pancreatic tumours and 
43% of all upper airway tumours were confirmed. Nevertheless, 
all melanomas and other cancers in the validation cohort were 
verified since the majority of diagnoses were derived from the 
Swedish Cancer Registry.
In conclusion, we have developed and validated a non-com-
puterised and clinically easy-to-use scoring system that shows 
high utility in predicting the probability of a germline CDKN2A 
mutation in melanoma-prone families from Northern Europe. 
The scoring system is based on clinical information on melanoma 
diagnoses in the patient’s family and additionally includes diag-
noses of PC and UAC. As CM-Score was trained and validated 
in large sets of Northern European families, we suggest that the 
system should be further validated in other regions as well. In 
view of the 10% mutation probability threshold, we suggest that 
CDKN2A analysis should be recommended to families with a 
CM-Score of ≥16 points.
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